Mitchell Shirvan is CSO at Silexion Therapeutics Corp (SLXN). They have made 1 open-market trade across 1 company since 2026, most recently 2026-06-04.
CIK 0001727789
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| FOMX | 24,980 | $75K |
| SLXN | 8,789 | $1K |
| Total | $76K |
Shares reported on the most recent Form 4, priced at the 2026-06-08 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SLXN | SELL | 2026-03-26 | 2026-03-30 | $1.36 | $31K | -11.0% | +434.7% | +139.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.